I agree, the lower price is so much more appropriate given the ridiculous drug cost we have. It was my impression the $110k price was created when it was advantageous to show the value of the inventory Samsung was manufacturing for us. Now that we are upon BLA filing and that inventory can be considered an asset, the $120k price might be just to be used in negotiations for financing. I don't think we know what the pricing will be at all and it could change based on insurance coverage and use.